Canadian Partnership for Tomorrow governance update

Posted November 6, 2008

Governance structure, key elements of study design now in place

The Governance Committee of the Canadian Partnership for Tomorrow Project will be chaired by Dr. John Potter and includes distinguished Canadian and international cancer experts.

Dr. Potter is senior advisor at the Fred Hutchinson Cancer Research Center in Seattle, Wash.

The study design has been moving ahead rapidly since the multi-partner project was announced in June.

Launch of Canadian 30-year cancer prevention study

Looking ahead

The next stages for the project include the following:

Governance committee members

Project principal investigators

Back row (left to right): Dr. Knoppers, Dr.  Benoît Lussier (Program Director, Partnership’s Research Action Group), Dr. Robson, Dr. Gallagher
Front row: Dr. McLaughlin, Dr. Parker

Back row (left to right): Dr. Knoppers, Dr. Benoît Lussier (Program Director, Partnership’s Research Action Group), Dr. Robson, Dr. Gallagher
Front row: Dr. McLaughlin, Dr. Parker

About the project

The Canadian Partnership for Tomorrow Project was announced in June 2008.

It is building on the successful foundation of the Alberta Health Service’s Tomorrow Project. The Alberta project is exploring the effects of cancer risks and preventative factors over time.

Now expanding nationwide, the project aims to collect health and lifestyle information from a randomly selected group of 300,000 Canadians. This group will be asked to complete questionnaires and provide biological samples over the next 20 to 30 years.

The Canadian Partnership for Tomorrow Project is being driven forward by the Canadian Partnership Against Cancer and partner organizations in five regions: the BC Cancer Agency, Alberta Health Services, Cancer Care Ontario with the Ontario Institute for Cancer Research, Quebec’s CARTaGENE project, and Cancer Care Nova Scotia and Dalhousie University collaborating for work in the Atlantic Provinces.

The results will help researchers, policy-makers and others understand how different combinations of risk factors lead to cancer and will serve as an important legacy for future generations.